Literature DB >> 15127367

"Collateral damage" from cephalosporin or quinolone antibiotic therapy.

David L Paterson1.   

Abstract

"Collateral damage" is a term used to refer to ecological adverse effects of antibiotic therapy; namely, the selection of drug-resistant organisms and the unwanted development of colonization or infection with multidrug-resistant organisms. The risk of such damage can be assessed for different antibiotic classes by a variety of epidemiologic studies. Cephalosporin use has been linked to subsequent infection with vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, beta-lactam-resistant Acinetobacter species, and Clostridium difficile. Quinolone use has been linked to infection with methicillin-resistant Staphylococcus aureus and with increasing quinolone resistance in gram-negative bacilli, such as Pseudomonas aeruginosa. Neither third-generation cephalosporins nor quinolones appear suitable for sustained use in hospitals as "workhorse" antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15127367     DOI: 10.1086/382690

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  107 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

Review 2.  Asymptomatic bacteriuria: when the treatment is worse than the disease.

Authors:  Barbara W Trautner
Journal:  Nat Rev Urol       Date:  2011-12-06       Impact factor: 14.432

3.  Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.

Authors:  Ronen Ben-Ami; Keren Olshtain-Pops; Michal Krieger; Ilana Oren; Jihad Bishara; Michael Dan; Yonit Wiener-Well; Miriam Weinberger; Oren Zimhony; Michal Chowers; Gabriel Weber; Israel Potasman; Bibiana Chazan; Imad Kassis; Itamar Shalit; Colin Block; Nathan Keller; Dimitrios P Kontoyiannis; Michael Giladi
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study.

Authors:  Lucas Magedanz; Erci Maria Silliprandi; Rodrigo Pires dos Santos
Journal:  Int J Clin Pharm       Date:  2012-03-01

5.  Variability in antibiotic use at children's hospitals.

Authors:  Jeffrey S Gerber; Jason G Newland; Susan E Coffin; Matt Hall; Cary Thurm; Priya A Prasad; Chris Feudtner; Theoklis E Zaoutis
Journal:  Pediatrics       Date:  2010-11-15       Impact factor: 7.124

Review 6.  Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance.

Authors:  Robert A Britton; Vincent B Young
Journal:  Trends Microbiol       Date:  2012-05-15       Impact factor: 17.079

7.  Antibiotic prescribing for ventilator-associated pneumonia: get it right from the beginning but be able to rapidly deescalate.

Authors:  Jean Chastre
Journal:  Intensive Care Med       Date:  2005-09-07       Impact factor: 17.440

8.  Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.

Authors:  Thomas M Hooton; Pacita L Roberts; Ann E Stapleton
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

9.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

10.  Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit.

Authors:  E Meyer; F Schwab; A Pollitt; W Bettolo; B Schroeren-Boersch; M Trautmann
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.